Development and Evaluation of a Quantitative Systems Pharmacology Model for Mechanism Interpretation and Efficacy Prediction of Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Patients with Non-Small-Cell Lung Cancer

Development and Evaluation of a Quantitative Systems Pharmacology Model for Mechanism Interpretation and Efficacy Prediction of Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Patients with Non-Small-Cell Lung Cancer

Immunotherapy has shown clinical benefit in patients with non-small-cell lung cancer (NSCLC). Due to the limited response of monotherapy, combining immune checkpoint inhibitors (ICIs) and chemotherapy is considered a treatment option for advanced NSCLC. However, the mechanism of combined therapy and...

Full description

Bibliographic Details
Main Authors: Chen-Yu Wang, Hao-Ran Dai, Yu-Ping Tan, Di-Hong Yang, Xiao-Min Niu, Lu Han, Wen Wang, Ling-Ling Ma, Aleksi Julku, Zheng Jiao
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Pharmaceuticals
Subjects:
quantitative systems pharmacology
atezolizumab
nab-paclitaxel
carboplatin
non-small-cell lung cancer
Online Access:https://www.mdpi.com/1424-8247/17/2/238

Similar Items

Similar Items